Introduction
Hemoptysis is often an alarming and worrisome symptom for the patient and the physician. Although massive hemoptysis occurs in less than 20% of the cases [1] , it can have devastating consequences. Technological advances have enabled a more e ective management, especially with the introduction of bronchial artery embolization and the improvements in computed tomography and bronchoscopy. Bronchoscopy remains an important diagnostic and therapeutic procedure in hemoptysis. New techniques to control bleeding have been reported with interesting results, and older approaches have been improved. is review addresses the approach of hemoptysis in the modern era, with particular emphasis on bronchoscopy.
Definition
Hemoptysis can be of variable severity ranging from slightly blood-streaked sputum to life-threatening hemorrhage [2, 3] . Severe hemoptysis should be promptly identi ed as it presents a signi cant mortality risk which has been reported to be as high as 80% without appropriate management [4] [5] [6] [7] [8] . Nearly all de nitions of severe or massive hemoptysis in the literature rely on the reported volume of expectorated blood in a 24-hour period. ere is no consensus on a speci c volume threshold for an hemoptysis to be considered massive [9, 10] . Studies use di erent thresholds ranging from 100 mL [11] to over 1000 mL [12] . De nitions relying on selfreported volumes are imperfect as patients may overestimate or underestimate volume as massive hemoptysis, understandably, causes signi cant stress [10] . We recommend to measure hemoptysis volume when patients are admitted to the hospital to have an objective assessment of clinical evolution, but unfortunately, such precise measures are seldom available on initial presentation.
Etiology
All hemoptysis etiologies can potentially cause massive hemoptysis. A broad di erential diagnosis of hemoptysis is summarized in Table 1 [4, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . e most frequent causes of hemoptysis vary signi cantly geographically and depending on the clinical setting. Certain causes of hemoptysis have a greater tendency to be massive [18] , while others are seldom massive. e ve most frequent causes of massive hemoptysis worldwide, in random order, remain bronchiectasis, lung cancer, tuberculosis [4] , lower respiratory tract infections, and mycetomas [16] . eir prevalence will vary from center to center because of demographic reasons as is demonstrated in Table 2 [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . However, despite a thorough investigation, an important proportion of hemoptysis remains cryptogenic-up to 50%-as reported by a recent 5-year retrospective study of the French nationwide hospital database [38] .
Diagnosis
e investigations of choice to diagnose the cause and localize the source of hemoptysis will vary depending on the past medical history and current presentation of a patient. Chest X-ray (CXR) remains the initial test performed in the majority of cases [39] . It determines the site of bleeding in 45 to 65% of the cases and the cause in 25 to 35% [32, 40, 41] . However, as much as 10% of pulmonary malignancies are occult on CXR, 96% of which will be detected by computed tomography (CT) [42] . For this reason, in the presence of a normal CXR, further investigation is often necessary, especially in the context of lung cancer risk factors [39] . Whether bronchoscopy or CT should be performed next has been a subject of controversy, but recent studies tend to demonstrate the superiority of CT to diagnose the cause of hemoptysis. In a prospective series including 87 patients with severe hemoptysis, Chalumeau-Lemoine et al. [43] demonstrated equivalence between exible bronchoscopy and CT to localize the source of bleeding. However, CT was signi cantly better to determine the cause of hemoptysis (86% versus 70%, p � 0.007) and resulted in a change in treatment approach in 22%. Nielsen et al. [44] showed that bronchoscopy does not add signi cant bene t to CT sensitivity when performed to rule out cancer after an episode of hemoptysis (0.97 versus 0.92, p � 0.58). Bønløkke et al. [45] obtained similar results in a retrospective review of 379 patients. CT is also an important tool to help guide an embolization procedure [46] [47] [48] .
During diagnostic testing for severe hemoptysis, it is important to remember that securing the patient's airway is always the priority. Performing a CT requires the patient to be transported into a setting where the clinician may be suboptimally equipped to manage a massive bleed. In certain situations, it is preferable to prophylactically secure the patient's airway prior to transportation to the radiology department, but cases need to be evaluated individually. Although CT is superior in identifying the cause of bleeding, bronchoscopy has several advantages over CT. Bronchoscopy can be performed at the bedside and does not require the patient to be transported. It can be a useful tool to help secure the airway if the bronchoscopist is experienced with pulmonary isolation techniques, and it can allow endobronchial treatments as mentioned later in this review. However, when there is active hemoptysis, bronchoscopy can stimulate coughing and therefore increase bleeding. For that reason, it is often safer to delay the bronchoscopy until initial bronchial artery embolization has been performed when the patient presents with severe hemoptysis.
Treatment

Bronchial Artery Embolization.
Bronchial artery embolization (BAE) was rst described by Rémy et al. [49] in 1974. Since then, the procedure has been improved and has become an essential tool for the management of hemoptysis. It is important to remember that most hemoptysis originate from the bronchial circulation, but in rare cases, hemoptysis may originate from the pulmonary circulation. Recent studies have shown the e ectiveness of BAE in a wide array of pathologies including tuberculosis, bronchiectasis, aspergilloma, and malignancy [50] [51] [52] [53] . Embolizing agents are numerous, but polyvinyl alcohol (usually 300-600 µm) is the most frequently used, having the advantage of being nonabsorbable and available in di erent sizes [54, 55] .
e most feared complication of BAE is embolization of the anterior spinal arteries, resulting in spinal cord ischemia. Over the last years, with the introduction of superselective catheterization, this complication is now uncommon (0-1%) [51] [52] [53] . BAE has proved its e cacy in hemoptysis of all degrees of severity, with a reported immediate clinical success rate of 82 to 98% [52, 53] . However, the longer term recurrence rate remains high, with reported values of 10 to 57% in recent studies [56, 57] . Recurrence can be secondary to incomplete embolization of all abnormal arteries, recanalization of previously embolized arteries, or recruitment of new collaterals [54] . Many factors have been associated with a higher risk of recurrence: malignant diseases [58] , aspergilloma [59, 60] , idiopathic bronchiectasis [57] , and oozing or active bleeding on exible bronchoscopy [1] . No data of quality assess the short-and long-term success rate of repeat embolization to our knowledge.
Endoscopic Treatment.
e role of bronchoscopy in severe hemoptysis is not limited to a diagnostic role. Bronchoscopists may need to intervene on iatrogenic bleeding caused during a procedure since they perform procedures such as transbronchial biopsies which are associated with signi cant bleeding in 2.8% of the cases [61] . For noniatrogenic hemoptysis, exible bronchoscopy is an essential procedure allowing at the same time identi cation of the source of bleeding, endoscopic treatment, and performance of pulmonary isolation to protect the una ected lung. In recent years, many bronchoscopic techniques have been reported to manage signi cant hemorrhages with an interesting success rate [16] .
For bronchoscopy to be safely performed in severe hemoptysis, an experienced bronchoscopic team and adequate equipment are needed. As previously mentioned, maintaining airway patency is a priority, requiring in some situations endotracheal intubation prior to a procedure or rigid bronchoscopy. If endotracheal intubation is performed, one must remember to use a large endotracheal tube to allow the passage of a therapeutic exible bronchoscope which is preferred in case of hemoptysis because of its larger working channel which provides better suction. Rigid bronchoscopy allows bronchoscopists to perform local tamponade of the bleeding if the source is central and to use a wide variety of endoscopic techniques. Rigid bronchoscopy also allows selective intubation for pulmonary isolation in case of catastrophic bleeding. [62] reported the successful use of cold saline lavage to control bleeding in 23 patients with massive hemoptysis (≥600 mL/24 h). rough a rigid bronchoscope, they performed a lavage with an average volume of 500 ml of 4°C normal saline. One patient presented sinus bradycardia and two subjects had rebleeding which required further lavage. After subsequent medical or surgical treatment, all patients were discharged free of hemoptysis. Large-volume cold saline lavages have not been studied again in more recent trials. However, smaller volume of cold saline is frequently used to control bleeding during bronchoscopy. To our knowledge, the e cacity of small-volume endobronchial cold saline to control endobronchial bleeding has never been studied.
Cold Saline. In 1980, Conlan and Hurwitz
Vasoconstrictive Agents.
e use of vasopressin analogs to control hemoptysis was rst reported in 1989 by Breuer et al. [63] who compared the e cacy of intravenous and endobronchial glypressin during diagnostic bronchoscopy.
e hemostatic e ect was similar, but intravenous administration was associated with a plasma concentration 251 times higher than endobronchial administration, resulting in a signi cantly higher diastolic pressure. In 2004, Tüller et al. [64] demonstrated in a retrospective study that terlipressin or ornipressin stopped bleeding in 30 patients with persistent bleeding after 2 minutes of suctioning or with major bleeding. ere was no short-term recurrence. Terlipressin was associated with a small but statistically signi cant impact on heart rate and blood pressure. 
Endobronchial Biocompatible Glue.
Endobronchial n-butyl cyanoacrylate glue is a biocompatible product which is adhesive and solidi es on contact with humidity. Its e cacy has been evaluated in three case series to our knowledge [67] [68] [69] , with interesting results. Bhattacharyya et al. [69] obtained immediate response in six patients. One patient required a repeat procedure on the day of the initial procedure. One long-term recurrence was noted after a mean follow-up of 127 ± 67 days.
is patient with bronchiectasis was observed without further intervention and evolved favorably. Coi ard et al. [68] described the case of a 76-year-old woman with a metastatic pulmonary adenocarcinoma who had persistent hemoptysis despite two attempts of BAE and failure of endobronchial spigot placement. Cyanoacrylate-based glue was mixed with iodinated contrast to allow uoroscopic guidance and followup imaging of the position of the glue. e immediate response rate was good, and no recurrence was observed at 48 hours. Chawla et al. [70] reported retrospectively the use of glue in 168 cases of mild or moderate hemoptysis persisting after 7 days of medical treatment or severe hemoptysis. Immediate control of hemoptysis was achieved in 151 patients (89.9%). All 17 patients without immediate control demonstrated very short-term recurrences, and they all underwent repeat glue application.
irteen of them (7.7%) responded to a second glue application for an overall response rate of 97.6%. No recurrences were noted in a 6-month follow-up during which patients could be treated for conditions causing their hemoptysis.
Endobronchial Stents.
Endobronchial stents have been successfully used to treat hemoptysis secondary to endobronchial lesions. is technique has been described mainly as a palliative treatment in the context of advanced lung cancer. All reported cases showed good immediate outcomes [71] [72] [73] . Cases were published with silicone and covered selfexpandable metal stents.
Endobronchial Embolization Using Silicone
Spigots. Endobronchial embolization using silicone spigots (EESS) was rst described by Dutau et al. [74] . EESS is used to occlude segmental airways from which bleeding originates. After the bleeding segment has been identi ed, the spigot is grasped with biopsy forceps that are already inserted through the working channel of a exible bronchoscope. Some authors stabilize the airway rst with a rigid bronchoscope before performing exible bronchoscopy [75] . e spigot is then positioned to occlude the segmental airway from which the bleeding originates. Multiple case reports have described this technique in a variety of conditions [75] [76] [77] . An interesting case report of successful EESS after failed BAE was published by Kho et al. [76] . e spigots were removed 4 days later, without further recurrence. A retrospective review by Bylicki et al. [75] included 9 patients and demonstrated a success rate of 78%. EESS was a temporary technique in a majority of cases, with 7 patients referred next to BAE and 2 patients referred for thoracic surgery. One patient had EESS as a de nitive treatment. Spigots were removed after a median of 4 days, and 2 patients had late recurrence of hemoptysis.
Fibrinogen-rombin.
e injection of the prothrombotic brinogen-thrombin (FT) combination via exible bronchoscopy was rst reported by Tsukamoto et al. [78] .
ey retrospectively reported 19 cases in which thrombin was used alone. rombin alone was very e ective in 15 cases, partially e ective in one case, and ine ective in 4 cases.
e FT combination was used in 14 cases, which demonstrated a very good response in 11 cases and a partial response in 3 cases. In a prospective study of 11 patients with severe hemoptysis, de Gracia et al. [79] obtained immediate control of bleeding in all patients with the injection of an FT combination. Two patients had a short-term severe hemoptysis relapse, and one had a long-term recurrence. Other case reports and small series demonstrated similar results [80, 81] .
Laser Photocoagulation.
Laser photocoagulation was introduced by Dumon et al. [82] in 1982. Multiple types of medical lasers are now available. e main di erence between lasers is their wavelength. With di erent wavelengths, the e ect of the laser on the treated tissue will vary. Nd : YAG and Nd : YAP lasers, with respective wavelengths of 1060 and 1340 nm, are the most frequently used lasers in bronchoscopy as they provide a better coagulation e ect. On the other hand, lasers such as CO 2 lasers have a far greater wavelength, 10,600 nm, and will provide more of a cutting e ect.
Han et al. [83] described in a retrospective review the e cacy of laser treatment for symptomatic palliation in a population of patients with central airway tumor. Out of 110 patients, 52 presented with hemoptysis. Hemoptysis completely resolved in 77% after laser treatment and partially improved in 17%.
ere was no procedure-related mortality. Another review of endoscopic palliative treatment of tracheobronchial tumors [84] showed a lower relatively short-term e cacy rate, with 58% of the patients being free of hemoptysis for 1 month or more following laser treatment. In other case reports, laser was also e cient in treating signi cant hemoptysis secondary to large central lesions [85, 86] .
Argon Plasma Coagulation.
Plasma is a term used to describe an electrically conducting medium produced when the atoms in a gas become ionized. Argon plasma can be used to conduct an electric current from a probe inserted through the working channel of a exible bronchoscope to an airway lesion. is electric current will then transform to thermal energy on contact with the tumor and coagulates its surface. Once coagulation of an area of the lesion is complete, the bronchial wall becomes less conductive and prevents deeper penetration of the electrical current in the airway wall which could lead to perforation [87] . Compared to laser photocoagulation during which the laser ber needs to be aimed perpendicularly to the treated tissue, argon plasma coagulation can treat lesions that are parallel or perpendicular to the probe as the electrical current will travel through the plasma to the closest mucosal area which is the path of least resistance [88] . In a retrospective review of patients with endobronchial lesions and hemoptysis, Morice et al. demonstrated an immediate bleeding control rate of 100% with argon plasma, without recurrence on a mean follow-up period of 97 ± 92 days. Apart from its use on endobronchial tumors, argon plasma coagulation was also used in cases of hemangioma [89] [90] [91] and endobronchial endometriosis [92] .
Endobronchial Valves.
Endobronchial valves were developed for endoscopic lung volume reduction in severely emphysematous patients with pulmonary hyperin ation [93] .
ese one-way valves allow air to escape from a pulmonary lobe but not enter it, therefore inducing atelectasis if there is no collateral ventilation. For management of massive hemoptysis, two case reports were published [94, 95] in patients with sequelae of tuberculosis who were successfully treated with endobronchial valves.
is approach remains anecdotic. It is important to remember that there is a signi cant proportion of pneumothorax after positioning endobronchial valves [96] .
is can lead to dramatic outcomes in the context of severe hemoptysis.
Pulmonary Isolation.
e objective of pulmonary isolation techniques in hemoptysis is to prevent blood from the bleeding lung to enter the normal lung and, consequently, to maintain ventilation and oxygenation of the patient. A rst simple maneuver is to place the bleeding source in a dependent position by turning the patient on the side of the bleeding. Trendelenburg and reverse Trendelenburg positions may also be useful depending on the position of the source of bleeding. Although elegant, positioning is not always su cient to control blood in the bleeding lung and is not a practical solution for further management; hence, formal pulmonary isolation is occasionally needed for severe hemoptysis cases. Available pulmonary isolation techniques include selective endobronchial intubation (SEI), placement of a bronchial blocker (BB) after endotracheal intubation, and intubation with a double-lumen endotracheal tube (DLT) (Figure 1 ). Pulmonary isolation is not to be taken lightly, especially in an unstable patient with active severe hemoptysis.
is was demonstrated by a prospective study [97] during which anesthesiologists with limited thoracic experience were asked to insert a double-lumen endotracheal tube, a Univent bronchial blocker (Fuji ™ , Tokyo, Japan), and an Arndt bronchial blocker (Cook Medical ™ , Bloomington, IN, USA) in an elective surgery setting. Twenty-two procedures were attempted with each device for a total of 66. Twenty-ve (38%) attempts resulted in failures. Failure rates were similar with all the three devices. Six minutes after passage of the vocal cords with the endotracheal tube, less than half of the devices were positioned properly, while after ten minutes, more than one-third of the devices were not successfully positioned. Canadian Respiratory Journal
Selective Endobronchial Intubation. SEI involves ad-
vancing an endotracheal tube into the mainstem bronchus contralateral to the bleeding site. is technique is generally performed under direct visualization with the bronchoscope guiding the tube into the mainstem bronchus before inating the balloon. is technique is, in our opinion, the easiest to perform, requires no special equipment, and has the lowest cost. e main disadvantage of this technique is the risk of migration of the tube proximally. is risk is especially signi cant when the right mainstem bronchus, which is shorter, needs to be intubated. In this situation, the bronchoscopist must be careful not to occlude the right upper lobe.
Bronchial Blocker.
Various devices can be passed through or beside an endotracheal tube to isolate the source of bleeding. e most frequently used devices include the Cohen tip-de ecting BB (Cook Medical, Bloomington, IN, USA), the Arndt BB (Cook Medical, Bloomington, IN, USA), and the Univent BB (Fuji, Tokyo, Japan) (Figure 2 ).
e Cohen BB is advanced through an endotracheal tube and has a wheel to direct its tip. e Arndt BB is guided into position by passing a bronchoscope through a loop at the end of the BB and using the bronchoscope as a guide to slide the blocker in place. e Univent BB is an endotracheal tube with a channel embedded in its wall. Once the endotracheal tube is in place, the BB can be advanced into proper position under bronchoscopic guidance. Its distal tip is curved, and rotation of the proximal end of the BB allows to guide its distal end into the desired mainstem. e main advantage of the BB is that they can be used to isolate a lobe or even a segment and they simply need to be de ated to explore the bleeding source distally.
Double-Lumen
Tube. e DLT consists of two single lumens bounded together, with the longer lumen positioned in the mainstem bronchus, while a shorter lumen is positioned in the trachea to ventilate the other lung (Figure 1 ).
e two main advantages of the DLT are that it allows ventilation of both lungs and that its positioning does not require to know the side from which the bleeding originates.
e main disadvantages of the DLT include the technical di culty in properly positioning and the small size of the two lumens which do not allow the passage of a therapeutic bronchoscope.
Tranexamic Acid.
Tranexamic acid (TXA) is a lysine derivative that inhibits brinolysis through the blockage of lysine-binding sites on plasminogen [98] . Traditionally, it has been used to diminish blood loss following trauma [99] , in the treatment of heavy vaginal bleeding [100] and in the perioperative management of major surgeries [101] . A limited number of trials have studied the e cacy of the administration of TXA in hemoptysis. In 2013, Moen et al. reviewed 13 articles representing the best available evidence to address the question, "Does tranexamic acid stop hemoptysis?" [102] . Although heterogeneous in design, study population, and quality of evidence, the papers indicated that TXA may reduce both the duration and volume of hemoptysis. However, development of pulmonary embolism was described in two di erent case reports of patients receiving TXA. A Cochrane systematic review including two randomized controlled trials (RCTs) evaluating the e ectiveness and safety of anti brinolytic agents in hemoptysis of all causes was also published in 2012 and revised in 2016 [103] . e pooled results of the 2 RCTs from ailand [104] (46 patients, oral administration of TXA) and Ruiz [105] (24 patients, intravenous TXA) showed a signi cant reduction in bleeding time in favor of the TXA group but no e ect on the remission of hemoptysis at seven days.
Bellam et al. [106] conducted a randomized, controlled pilot study in 2016 comparing IV perfusion of TXA to placebo in 66 patients with submassive hemoptysis. Results showed a nonsigni cant trend favoring TXA over placebo in terms of frequency and quantity of hemoptysis, need for intervention and blood transfusion, and duration of hospital stay. No adverse event was noted in the treatment arm.
While oral and intravenous routes have been the most commonly used for the administration of tranexamic acid, novel approaches have received clinical attention. In a small number of cases, aerosolized TXA and endobronchial instillation of TXA during bronchoscopy showed promising results in the treatment of hemoptysis [57, [107] [108] [109] [110] [111] .
Even though limited research is available on the administration of tranexamic acid as a therapeutic option for hemoptysis, existing evidence appears consistent with a reduction in bleeding quantity and duration. Further clinical studies are needed, but TXA deserves consideration and may prove to be a valuable option for the treatment of severe hemoptysis. Future studies should consider that tranexamic acid has a very short half-life and, at that time, did not demonstrate e ectiveness in trauma until administered as a continuous perfusion.
Surgery.
Surgery is an e ective modality to control hemoptysis in patients with localized disease [4] , but patients undergoing surgery have reported mortality rates between 2% and 18% which may be a marker of severity of the underlying disease [29, 112, 113] . e mortality rate increases further when the surgery is extensive or performed in an emergency setting, reaching up to 50% [29, 114] . However, in survivors, recurrence rates are relatively low. Kiral et al. reported a 4% mortality rate with a mean follow-up of 23 months [29] . Surgery is also especially useful for conditions with a high risk of recurrence after bronchial artery embolization. For patients in whom surgery is the treatment of choice but who are not candidates on presentation, BAE can be a useful temporizing measure [115] . A multidisciplinary discussion including the surgeon, respirologist, and radiologist is often necessary in order to determine optimal management.
Conclusion
Hemoptysis remains an important and sometimes challenging medical issue. No diagnostic modality is universally superior, and each case needs to be individually approached. While bronchial artery embolization remains the cornerstone of the management of severe or persistent hemoptysis, many new endoscopic procedures have demonstrated signs of e cacy in recent years. Further data need to be obtained about the longer term results of these procedures. Comparison to placebo in addition to standard of care is also necessary, since hemoptysis frequently resolves spontaneously. Larger placebo-controlled trials of tranexamic acid perfusion in hemoptysis would also be of interest. Little is known about hemoptysis, and it remains an area of interest for future research.
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